-
公开(公告)号：US20130018085A1
公开(公告)日：2013-01-17
申请号：US13620212
申请日：2012-09-14
Applicant: Antonin de Fougerolles , Maria Frank-Kamenetsky , Muthiah Manoharan , Kallanthottathil G. Rajeev , Philipp Hadwiger
Inventor： Antonin de Fougerolles , Maria Frank-Kamenetsky , Muthiah Manoharan , Kallanthottathil G. Rajeev , Philipp Hadwiger
IPC: A61K31/713 , A61P35/00 , A61P27/02 , C12N5/071 , C07H21/02
CPC classification number: C12N15/1136 , A61K9/0019 , A61K31/7088 , A61K31/712 , A61K31/713 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/549 , A61K47/551 , A61K47/60 , A61K48/00 , C07K14/475 , C12N2310/14 , C12N2310/3515 , C12N2310/533 , C12N2320/30 , C12N2320/32
Abstract: The features of the present invention relate to compounds, compositions and methods useful for modulating the expression of vascular endothelial growth factor (VEGF), such as by the mechanism of RNA interference (RNAi). The compounds and compositions include iRNA agents that can be unmodified or chemically-modified.
-
公开(公告)号：US08344127B2
公开(公告)日：2013-01-01
申请号：US13090580
申请日：2011-04-20
Applicant: Antonin De Fougerolles , John L. Diener , Emma Hickman , Gregory Hinkle , Stuart Milstein , Anne-Marie Pulichino , Andrew Sprague
Inventor： Antonin De Fougerolles , John L. Diener , Emma Hickman , Gregory Hinkle , Stuart Milstein , Anne-Marie Pulichino , Andrew Sprague
CPC classification number: C12N15/1138 , A61K31/713 , C12N2310/111 , C12N2310/14 , C12N2310/31 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/344 , C12N2310/351 , C12N2310/3513 , C12N2310/3515 , C12N2310/3517 , C12N2310/3521
Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
Abstract translation: 本公开涉及可用于使用治疗有效量治疗β-ENAC相关疾病如囊性纤维化，1型假性醛固酮增多症（1例（PHA1），跛行综合征，高血压，碱中毒，低钾血症和肥胖相关性高血压）的方法中的RNAi剂 的RNAi试剂到β-ENaC。
-
53.发明申请Lipid Formulated Compositions and Methods for Inhibiting Expression of a Gene from the Ebola Virus 有权用于抑制埃博拉病毒基因表达的脂质制剂组合物和方法公开(公告)号：US20120270921A1
公开(公告)日：2012-10-25
申请号：US13390095
申请日：2010-08-13
Applicant: Antonin de Fougerolles , Anna Borodovsky , Tatiana Novobrantseva
Inventor： Antonin de Fougerolles , Anna Borodovsky , Tatiana Novobrantseva
IPC: A61K31/713 , C12N5/071 , A61P31/14
CPC classification number: A61K48/0075 , A61K47/22 , C12N15/111 , C12N15/1131 , C12N2310/14 , C12N2320/32
Abstract: The invention relates to lipid formulated double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a gene from the Ebola virus.
Abstract translation: 本发明涉及用于抑制埃博拉病毒基因表达的脂质配制双链核糖核酸（dsRNA）。
-
公开(公告)号：US08227188B2
公开(公告)日：2012-07-24
申请号：US12875695
申请日：2010-09-03
Applicant: Antonin de Fougerolles , Tatiana Novobrantseva , Pamela Tan , Anke Geicke , Rachel Meyers
Inventor： Antonin de Fougerolles , Tatiana Novobrantseva , Pamela Tan , Anke Geicke , Rachel Meyers
IPC: C12Q1/68
CPC classification number: C12N15/1131 , C12N2310/14 , C12N2310/331 , C12N2760/16111
Abstract: The invention relates to compositions and methods for modulating the expression of influenza viral genes, and more particularly to the downregulation of influenza viral genes by chemically modified oligonucleotides.
Abstract translation: 本发明涉及调节流感病毒基因表达的组合物和方法，更具体地涉及通过化学修饰的寡核苷酸下调流感病毒基因。
-
55.发明申请Compositions and Methods for Inducing an Immune Response in a Mammal and Methods of Avoiding an Immune Response to Oligonucleotide Agents Such as Short Interfering RNAs 审中-公开用于诱导哺乳动物免疫应答的组合物和方法以及避免对诸如短干扰RNA的寡核苷酸药物的免疫应答的方法公开(公告)号：US20120045461A1
公开(公告)日：2012-02-23
申请号：US13179421
申请日：2011-07-08
Applicant: Gunther Hartmann , Antonin de Fougerolles , Veit Hornung , Stefan Endres
Inventor： Gunther Hartmann , Antonin de Fougerolles , Veit Hornung , Stefan Endres
IPC: A61K31/7088 , A61P37/04 , A61K39/00 , C07H1/06 , C07H21/02
CPC classification number: C12N15/117 , A61K39/00 , A61K39/39 , A61K2039/53 , C12N15/1138 , C12N2310/14 , C12N2310/17 , C12N2310/3231
Abstract: Tis invention provides oligonucleotide agents that modulate an immune response by stimulating IFN production and methods of using such agents for therapeutic treatments of mammals.
Abstract translation: 本发明提供了通过刺激IFN产生来调节免疫应答的寡核苷酸试剂和使用这些试剂用于哺乳动物的治疗性处理的方法。
-
Patent Agency Ranking
56.发明授权Compositions and methods for inhibiting expression of a gene from the ebola virus 有权用于抑制基因从埃博拉病毒表达的组合物和方法公开(公告)号：US07973020B2
公开(公告)日：2011-07-05
申请号：US12789414
申请日：2010-05-27
Applicant: Sina Bavari , Kelly Lyn Warfield , Pamela Tan , Anna Borodovsky , Tatiana Novobrantseva , Antonin de Fougerolles
Inventor： Sina Bavari , Kelly Lyn Warfield , Pamela Tan , Anna Borodovsky , Tatiana Novobrantseva , Antonin de Fougerolles
CPC classification number: C12N15/1131 , C07H21/02 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3521 , C12N2310/3531
Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a gene from the Ebola virus.
Abstract translation: 本发明涉及用于抑制埃博拉病毒基因表达的双链核糖核酸（dsRNA）。
-
公开(公告)号：US07947659B2
公开(公告)日：2011-05-24
申请号：US11078073
申请日：2005-03-11
Applicant: Antonin de Fougerolles , Maria Frank-Kamenetsky , Muthiah Manoharan , Kallanthottathil G. Rajeev , Philipp Hadwiger
Inventor： Antonin de Fougerolles , Maria Frank-Kamenetsky , Muthiah Manoharan , Kallanthottathil G. Rajeev , Philipp Hadwiger
CPC classification number: C12N15/1136 , A61K9/0019 , A61K31/7088 , A61K31/712 , A61K31/713 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/549 , A61K47/551 , A61K47/60 , A61K48/00 , C07K14/475 , C12N2310/14 , C12N2310/3515 , C12N2310/533 , C12N2320/30 , C12N2320/32
Abstract: The features of the present invention relate to compounds, compositions and methods useful for modulating the expression of vascular endothelial growth factor (VEGF), such as by the mechanism of RNA interference (RNAi). The compounds and compositions include iRNA agents that can be unmodified or chemically-modified.
Abstract translation: 本发明的特征涉及用于调节血管内皮生长因子（VEGF）表达的化合物，组合物和方法，例如通过RNA干扰（RNAi）机制。 化合物和组合物包括可以未修饰或化学修饰的iRNA试剂。
-
公开(公告)号：US07888498B2
公开(公告)日：2011-02-15
申请号：US11751283
申请日：2007-05-21
Applicant: Antonin De Fougerolles , Andrew Sprague , Jens Harborth , Maria Gabriela Belvisi , Mark Andrew Birrell , Elizabeth Louise Hardaker , Matthew Copeland Catley
Inventor： Antonin De Fougerolles , Andrew Sprague , Jens Harborth , Maria Gabriela Belvisi , Mark Andrew Birrell , Elizabeth Louise Hardaker , Matthew Copeland Catley
CPC classification number: C12N15/1137 , C12N2310/111 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3515 , C12Y207/1101 , C12N2310/3521
Abstract: The invention relates to a doable-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the IKK-B gene, comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the IKK-B gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases, caused by the expression or activation of the IKK-B gene using the pharmaceutical composition; and methods for inhibiting the expression of the IKK-B gene in a cell.
Abstract translation: 本发明涉及用于抑制IKK-B基因表达的双链核糖核酸（dsRNA），其包含长度小于30个核苷酸，长度通常为19-25个核苷酸的核苷酸序列的反义链，以及 其基本上与IKK-B基因的至少一部分互补。 本发明还涉及包含dsRNA与药学上可接受的载体的药物组合物; 用于使用该药物组合物治疗由IKK-B基因的表达或活化引起的疾病的方法; 以及抑制细胞中IKK-B基因表达的方法。
-
公开(公告)号：US20110034537A1
公开(公告)日：2011-02-10
申请号：US12867230
申请日：2009-02-12
Applicant: Antonin De Fougerolles , Pamela Tan , Anna Borodovsky , Tatiana Novobrantseva , Sina Bavari , Kelly Lyn Warfield
Inventor： Antonin De Fougerolles , Pamela Tan , Anna Borodovsky , Tatiana Novobrantseva , Sina Bavari , Kelly Lyn Warfield
IPC: A61K31/713 , C07H21/02 , C12N5/10 , C12N5/071 , C12N15/63 , A61P37/02 , A61P31/12 , A61P31/16 , A61P31/14
CPC classification number: C12N15/1137 , C12N15/1138 , C12N2310/113 , C12N2310/14 , C12N2310/17 , C12N2310/315 , C12N2310/321 , C12N2310/3515 , C12N2310/3521
Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the CD45 gene.
Abstract translation: 本发明涉及用于抑制CD45基因表达的双链核糖核酸（dsRNA）。
-
公开(公告)号：US20110033859A1
公开(公告)日：2011-02-10
申请号：US12875695
申请日：2010-09-03
Applicant: Antonin de Fougerolles , Tatiana Novobrantseva , Pamela Tan , Anke Geick , Rachel Meyers
Inventor： Antonin de Fougerolles , Tatiana Novobrantseva , Pamela Tan , Anke Geick , Rachel Meyers
IPC: C12Q1/68
CPC classification number: C12N15/1131 , C12N2310/14 , C12N2310/331 , C12N2760/16111
Abstract: The invention relates to compositions and methods for modulating the expression of influenza viral genes, and more particularly to the downregulation of influenza viral genes by chemically modified oligonucleotides.
Abstract translation: 本发明涉及调节流感病毒基因表达的组合物和方法，更具体地涉及通过化学修饰的寡核苷酸下调流感病毒基因。
-
-
-
-
-
-
-
-
-
Search Results
74
records
(took 0.065 seconds)
